NASDAQ:EFOI   Energy Focus, Inc.

I have been watching ABEO for about a month now. ABEO has the potential to make a few bucks but is relatively high on risk. I hesitate parking too much money here for too long but do believe this will reap rewards in 6-12 months.

Some reasoning goes as follows:
1) Legitimate company that is in the middle of working on multiple gene therapy products for rare conditions.
2) Past spike was caused by announcements of news and positive news regarding one product
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
Feb 12, 2021
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
Feb 3, 2021
3) There will be multiple announcements coming this year
Completion of patient enrollment for the EB-101 Phase 3 VIITAL™ study in the first quarter of 2022
Top-line VIITAL™ study results in the third quarter of 2022

Construct and operationalize the new AAV manufacturing facility in 2022
Top-line results for MPS IIIA Transpher A study between the fourth quarter of 2022 and second quarter of 2023

Two-year neurocognitive data from MPS IIIB Transpher B study in the second half of 2022
Preclinical Pipeline
Generate proof-of-concept data assessing AAV capsids in multiple undisclosed eye indications beginning in the first half of 2022
Pre-IND meeting with FDA in the second half of 2022

4) The announced public offering of stock has been gobbled up while the price remains flat. This points to accumulation.

I would be looking to put 5% of my trading capital into this stock at a price point of .27 and the price target is $3 even. Obviously a 10 bagger is rare, but this might have some potential.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.